Concordance of Pain Detection in Patients by Doloplus® and Algoplus® Behavioural Scales
NCT ID: NCT02174744
Last Updated: 2014-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
210 participants
OBSERVATIONAL
2014-01-31
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The evaluation of pain appeals to the same strategy as to the younger subject but with some specificities, related more to the pathologies associated with the ageing than to the real age. For that purpose, the investigators have self-assessment scales as the Numeric Pain Rating Scale which is adapted to estimate acute and chronic pains, but this scale presents a bias because, some patients do not express spontaneously their pain.
So behavioural scales were elaborated to solve the difficulties of detection and to care the pain of the elderly. The Algoplus® scale (5 items which takes less than one minute to be completed) whose objective is the observation of behavioural changes caused by the acute pain in elderly having communication disorders. The Doloplus® scale (30 items which allow in few minutes a good evaluation of pain) whose objective is the observation of behavioural changes caused by the chronic pain in elderly having communication impairments.
In practice, because of its popularity, the Algoplus® scale is widely used out of the specificity in which it has been validated. Practitioners, worried about this misuse, suggested to Doloplus® group, to test the concordance between the two behavioural scales in order to develop recommendations more targeted. The risk is that the use of the Algoplus® scale may underestimate pain that would have been detected by Doloplus® scale, and lead to under-treatment or non-treatment of pain in elderly having communication disorders.
This study aims to establish the concordance between these two scales to generate advices and recommendations to assess efficiently the pain in this vulnerable population.
The main objective of this study is to assess whether the use of Algoplus® scale is in good concordance with Doloplus® scale.
The secondary objective of this study is to assess the concordance with different levels of Algoplus® pain scale: (0-1), (2-3), (4-5).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
International Validation Study Of The Algoplus Scale In Five Languages
NCT02018614
Impact of the Use of the Scale ALGOPLUS® on the Prescriptions of Analgesics in Emergency Department on Patients of 75 Years Old or More
NCT02258503
Dropout Factors in Chronic Pain Management
NCT04218227
Care-related Pain and Discomfort in People With Motor Disorder
NCT02720731
Effectiveness of Relational Touch in Painful Elderly
NCT01837732
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In a first step, 48 hours after patient admission in the care service, a first doctor/caregiver will assess pain with Numeric Pain Rating Scale and evaluate MMSE score if it is possible and then assess pain with the Algoplus® scale. The results of the Numeric Pain Rating Scale, the Algoplus® scale and the MMSE score will be recorded in the medical record and in the study Case Report Form.
In a second step, less than 3 hours after the first assessment, a second doctor/caregiver will assess pain with the Doloplus® scale and the result will be recorded in the medical record and in the study Case Report Form.
The Case Report Form (containing demographic data, the history of pain, analgesics treatment, scores of Numeric Pain Rating Scale, MMSE, Algoplus® scale and Doloplus® scale) will be faxed to the Coordinating Center at Clermont-Ferrand in the day.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
numerical scale
numeric pain rating scale
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
numeric pain rating scale
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients having communication disorders
* Hospitalization for at least 48 hours
Exclusion Criteria
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Gisèle PICKERING (MCU, PH) Center of clinical pharmacology/CIC Inserm-1405 - Main investigator - Coordinating center
UNKNOWN
Ms Joëlle DEVOT - Collaborator
UNKNOWN
Dr Patrice RAT - Investigator
UNKNOWN
Dr Chandra COLOM - Investigator
UNKNOWN
Mr Dieudonné ENDOUGOU - Collaborator
UNKNOWN
Dr Cyril GUILLAUME - Investigator
UNKNOWN
Ms Nathalie ROUX - Collaborator
UNKNOWN
Dr Yves PASSADORI - Investigator
UNKNOWN
Ms Nathalie DANNENBERGER - Collaborator
UNKNOWN
Dr Micheline MICHEL - Investigator
UNKNOWN
Dr Sylvie CHAPIRO- Investigator
UNKNOWN
Dr Jean-François VILLARD - Investigator
UNKNOWN
Dr Bernard WARY- Investigator
UNKNOWN
Dr Anne-Cécile BOURJAL - Investigator
UNKNOWN
Dr Catherine BLUNTZ - Investigator
UNKNOWN
Dr Françoise CAPRIZ - Investigator
UNKNOWN
Dr Marie FLOCCIA - Investigator
UNKNOWN
Dr Jérôme BOHATIER - Investigator
UNKNOWN
Ms Linh NGUYEN PHUONG - Collaborator
UNKNOWN
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gisèle PICKERING
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHU-0190
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.